Loading...
•
Dec 31, 2025
Bridgebio Q4 2025 Earnings Report
BridgeBio Pharma, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025.
Key Takeaways
BridgeBio saw significant revenue growth in Q4 2025, primarily driven by the commercial success of Attruby (acoramidis) following its 2024 FDA approval. The company achieved three positive Phase 3 trial readouts in late 2025 and is preparing for multiple NDA submissions in 1H 2026, transitioning into a multi-product commercial-stage biopharmaceutical company.
Total Q4 revenue reached $154.2 million, a massive increase from $5.9 million in the prior year, driven by Attruby net product sales.
Reported three positive Phase 3 trial readouts (PROPEL 3, FORTIFY, and CALIBRATE) within a three-month window.
On track for two NDA submissions in 1H 2026 for BBP-418 (LGMD2I/R9) and encaleret (ADH1).
Strengthened balance sheet with $587.5 million in cash and a subsequent $632.5 million convertible note issuance in January 2026.
Revenue by Segment
Forward Guidance
BridgeBio is focused on expanding its commercial portfolio from one to potentially six approved medicines by the end of its first decade, supported by recent Phase 3 successes.
Positive Outlook
- Planned NDA submission for BBP-418 in LGMD2I/R9 in 1H 2026.
- Planned NDA submission for encaleret in ADH1 in 1H 2026.
- Planned NDA submission for infigratinib in achondroplasia in 2H 2026.
- Anticipated U.S. launches for BBP-418 and encaleret in late 2026 or early 2027.
- Phase 2 data for infigratinib in hypochondroplasia expected in 2H 2026.
Challenges Ahead
- Ongoing net losses as the company scales commercial and R&D operations.
- Significant noncash interest expense on deferred royalty obligations.
- Dependence on regulatory approvals for the 2026/2027 launch timeline.
- Potential volatility in share price and macroeconomic impacts on operations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...